On March 31, Gregory D. Smith passed away after a long and successful career as the founder and chief executive officer of both Maplewood Senior Living and Inspir. He was 54.

There has been no announcement on the cause of his death. 

In 2006, Greg Smith, who resided in Norwalk and was known to most people as Smith, established the Maplewood brand. His goal was to set a higher standard for senior living communities by providing opulent living quarters, forward-thinking wellness programs, outstanding care, gracious hospitality, and cutting-edge technology.

Maplewood Senior Living, which has its headquarters in Westport, now operates 16 senior living homes around the United States, including in Ohio, New York, New Jersey, and Massachusetts. It also has locations in East Norwalk, Bethel, the Southport district of Fairfield, Orange, Newtown, Darien, and Danbury. The newest brand that the firm offers, Inspir, may be found in both New York City and Washington, District of Columbia.

“Greg’s passion was infectious and drove all of us to push the boundaries of what was possible,” Shane Herlet, the chief operating officer of Maplewood, said in a company statement. “We are proud to carry on his legacy and continue our work to deliver best-in-class senior living options. On behalf of our leadership team, employees and investment partners, we extend our deepest sympathies to his family and friends.”

A spokesman for Maplewood refused to speak anymore, claiming that staff members were unable to comment on Smith’s passing beyond the statement.

In 2015, Smith implemented one of his creative ideas by establishing a memory resource and support center at the Maplewood Senior Living community located on Stony Hill in Bethel. It presents some of the most recent findings from research as well as information on memory-related diseases such as Alzheimer’s disease and dementia.

The center for the treatment of patients with Alzheimer’s disease and other illnesses that influence memory may be found inside the assisted-living facility, which was developed specifically for the treatment of such patients.